It has been announced that Precia, a precision drug delivery company, has partnered with Battelle's research and development experts to develop groundbreaking 3D printing platforms that will revolutionize the way medicines are developed, manufactured, distributed, and administered by the next generation. A number of industries have been revolutionized by the advent of 3D printing technology, and now it is poised to disrupt pharmaceutical production.
There are a number of complex processes involved in the traditional pharmaceutical manufacturing process, as well as long production times and limitations associated with custom dosage forms. Due to the capabilities of Aprecia Pharmaceuticals' 3D printing platforms, these challenges can be overcome through the creation of highly customized, patient-specific medicines.. Precia's Z-FORM 3D printing platform technology, combined with artificial intelligence and machine learning-based process analytical technologies (PAT), allows for precise layer-by-layer formation of customized pharmaceutical drug products produced directly in their primary packaging by integrating machine learning-based artificial intelligence.
Precia's Z-FORM 3D printing platform technology, combined with artificial intelligence and machine learning-based process analytical technologies (PAT), allows for precise layer-by-layer formation of customized pharmaceutical drug products produced directly in their primary packaging by integrating machine learning-based artificial intelligence.
As one of the key advantages of Aprecia's 3D printing platform, it is its ability to provide a wide range of functionally differentiated drug products that were previously impossible to produce using traditional manufacturing methods. As a result of this breakthrough technology, it can have a significant impact on many patient populations, including those who have difficulty swallowing large tablets. The Z-FORM 3D printing platform from Aprecia allows pharmacists and healthcare providers to customize the dose of medications to each individual patient, ensuring better patient compliance and improved therapeutic outcomes as a result.
The Z-FORM 3D printing platform from Aprecia allows pharmacists and healthcare providers to customize the dose of medications to each individual patient, ensuring better patient compliance and improved therapeutic outcomes as a result.
In order to provide solutions to unmet patient needs, Aprecia Pharmaceuticals' mission is to revolutionize the way pharmaceuticals are manufactured and administered, according to E.Thomas Arington, Chairman of the Aprecia Pharmaceuticals Board. With the use of Z-Form technology, customized medication could be developed for each patient individually.
In July 2021, Aprecia engaged Battelle to conduct an assessment of the feasibility of 3D printed, customized tablets which contained multiple active pharmaceutical ingredients as part of the development partnership. In the years since then, Battelle has been developing the concept into a working prototype system that is now ready to be tested and commercialized. 
"Partnerships are an excellent example of what Battelle does well when it comes to working with a successful technology company like Aprecia. As part of this project, Battelle gathered a variety of emerging and well-known technologies from a wide variety of markets to develop the first-of-its-kind capabilities that would solve meaningful and challenging problems for society, said Greg Kimmel, Vice President and General Manager of Battelle's Health business unit.. "There are some technologies that are just becoming commercially available, some of which are well-established, and some of which we have developed specifically for this program.".In the course of this project, many Battelle experts were involved in the design of complex hardware and software systems, which included electrical engineers, mechanical engineers, physicists, software developers and systems engineers.. It was an excellent collaboration that resulted in the ultimate success of this assignment. As a result of maintaining an open dialogue and positive relationship with Aprecia, the team has been able to adjust schedules and plans as needed in order to achieve its end goal"
As a result of maintaining an open dialogue and positive relationship with Aprecia, the team has been able to adjust schedules and plans as needed in order to achieve its end goal"
"Aprecia's development schedule required a very fast turnaround," said Melinda Sych, Senior Vice President and Chief Commercial Officer for Battelle. "Because they are located just an hour and a half away in Blue Ash, they frequently visit Battelle and collaborate with the Battelle team to solve technical problems as soon as they arise."
With the success of this current project, Aprecia will have a distinctive advantage over other conventional manufacturing companies. As a result of this combination of capabilities, Aprecia is able to produce highly customized, patient-specific medications with accurate dosages and the ability to formulate them in any way they choose. As a result of this scenario, there is the potential for improved patient compliance and outcomes while providing advantages in terms of cost and logistics. In the coming years, as 3D printing platforms continue to evolve and gain regulatory approval for a wider range of drug products, it is expected that they will revolutionize the way medicines are manufactured and delivered, ultimately improving the quality of life for patients around the world.
In the coming years, as 3D printing platforms continue to evolve and gain regulatory approval for a wider range of drug products, it is expected that they will revolutionize the way medicines are manufactured and delivered, ultimately improving the quality of life for patients around the world.
Aprecia's mission and vision
The Aprecia Group was founded in 2003, and in 2015, it received FDA approval for the first and only three-dimensionally printed (3DP) pharmaceutical product and today, it is the global leader in utilizing 3DP technology for commercial-scale, pharmaceutical manufacturing.. As part of Aprecia's proprietary 3DP technology, the company has developed a multi-patented, binder-jetting manufacturing process that is capable of both open-bed and in-cavity printing, as well as their advanced formulations and rapid prototyping capabilities.. As part of Aprecia's ZipDose® Technology Platform, Aprecia is able to produce rapid disintegrating oral dosage forms which are easy to take and easy to administer.. There are a number of benefits to licensing Aprecia's exclusive technology platform to pharmaceutical partners, including the extension of product lines, the improvement of patient reach and experience, as well as meeting FDA requirements as a pediatric delivery method.. If you would like to learn more, please visit our website:.Appreciate your support.The Comcast Corporation
The Comcast Corporation
?The Battelle Group
Battelle's people apply science and technology to solve the most important problems of the day with science and technology. Battelle is a global leader in research and development, design, manufacturing, and delivering critical services for government and commercial customers in a wide range of technology centers and national laboratories around the world. Battelle has been headquartered in Columbus, Ohio since 1929, and has been making world a better place by commercializing technology, giving back to our communities, and helping to support science, technology, engineering, and mathematics (STEM) education worldwide. Visit our website for more information about our services.The Battelle.The organization
The organization
Aprecia Pharmaceuticals is the source of this information
Get PRN's top stories and curated news delivered to your inbox every week by signing up!

Source prnewswire